American Society of Hematology Annual Meeting & Exposition

Videos

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, Discusses Autologous Stem Cell Transplantation for Patients with DLBCL

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple Myeloma

Articles

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

Quality of Life Improves Over Time for Patients With Aggressive Lymphomas

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Early Signs of Activity and Tolerability Found in Allogeneic Product UCART22 for Patients with Relapsed/Refractory CD22+ B-Cell ALL

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.

Hematologic Cancers Bear Increased Risk for Adverse COVID-19 Outcomes

Findings from a preclinical study suggested ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.

ALVR109 Displays Antiviral Activity, Suggested to be Safe, Effective Treatment for COVID-19

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

American Society of Hematology Annual Meeting & Exposition | Conference